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From the Clinic

A ﬁve-year-old boy presented (Day 0) with gingival bleeding and pancytopenia (white blood cells: 1.7 × 109/L;
hemoglobin: 7.3 g/dL; platelets: 16 × 109/L). A coagulation
panel was unremarkable. Peripheral blood smear revealed
dysmorphic promyelocytes with red-blue granules, folded
reniform nuclei and no Auer rods. Bone marrow examination showed immature myeloid cells (>60% promyelocytes) that were positive for myeloperoxidase (MPO),
CD117, CD13 and CD33, and negative for CD34 and HLADR. Cytogenetic analysis showed a male karyotype with
46,XY, t(15;17)(q24;q21). Quantitative real-time polymerase chain reaction was positive for PML-RARα. A diagnosis
of acute promyelocytic leukemia (APL) was established.
Induction chemotherapy with daunorubicin (50 mg/m2
Days 1, 3 and 5), cytarabine (100 mg/m2 every 12 h, Days
1–10) and thioguanine (100 mg/m2 every 12 h, Days 1–10)
along with all-trans retinoic acid (ATRA; 45 mg/m2 per day
in two divided doses starting on Day 1) was initiated on
admission Day 2. Prophylactic dexamethasone (0.1 mg/kg
twice daily) was administered along with ATRA. On Day 9,
the patient developed a hypertensive crisis, bilateral lower
extremity edema, proteinuria (24-h urine protein 1000
mg) and hyperlipidemia (triglycerides: 525 mg/dL, total
cholesterol: 275 mg/dL). His serum albumin at this time was
3.2 g/dL. Given the above presentation and the deﬁnition
of nephrotic-range proteinuria in children (>40 mg/m2/h), a

diagnosis of nephrotic syndrome (NS) (most likely minimal
change disease) was established and steroids (prednisone
2 mg/kg/day) were initiated. Proteinuria and other
manifestations of NS resolved on admission Day 26, after
which steroids were quickly tapered and eventually discontinued. The patient has now completed the second course
of DAT without signs or symptoms of NS. During the second
course, he only received prophylactic doses of steroids.
The association of NS with acute myeloid leukemia
(AML) is rare, with only 10 cases reported previously
(Table 1). There was a remarkable male predominance
(80%), and the median age at diagnosis was 33 (range: 3–
81) years. Surprisingly, 45% of all cases and all three pediatric cases were APL. NS was present before treatment in
45% of cases, suggesting a direct pathogenic role of leukemia. In other cases, anthracycline therapy was the main
culprit. Histopathological ﬁndings on renal biopsy did not
reveal a unique pattern and varied from minimal change
disease (MCD) to focal segmental glomerulosclerosis
(FSGS), immune complex deposition, macrophage inﬁltration, membranous glomerulonephritis, proliferative glomerulonephritis and detachment of epithelial cells from the
glomerular basement membrane. From the nine patients
who received some form of treatment for NS, steroids
were the chosen treatment in seven patients, with a response rate of 86%; the other two patients were treated
only with chemotherapy and NS responded to treatment
in both.
A number of mechanisms may explain the rare association between NS and AML. Disruption of podocyte integrity

Table 1. Summary of previous reports on the association between AML and NS

Induction regimen

Proteinuria
before AML
treatment

Possible
etiology

Renal histology

Tx of NS,
response

20, M, n/a

None

+

AML

Membranous GN

None

[9], 1983

57, M, M4

+

AML

FSGS, immune
complex deposits

Steroids
+

[11], 1986

81, F, M3

Vincristine and prednisone, followed
by cytarabine, daunorubicin, thioguanine,
and prednisone
None

+

n/a

Proliferative GN

[12], 1989

33, M, M2

Cytarabine, daunorubicin

–

Anthracycline

MCD, IgM deposits

[13], 1995

33, F, M3

Cytarabine, daunorubicin, 6-MP, prednisone

–

Anthracycline

[14], 1996

59, M, M2

+

M-CSF

[2], 2002

44, F, M5

Enocitabine, daunorubicin, 6-MP,
cytarabine, vincristine, prednisolone, M-CSF
Etoposide, cytarabine, daunorubicin

+

AML

Epithelial-GBM
detachment
Macrophage
inﬁltration
n/a, possible MCD

Steroids
–
Steroids
+
None

[15], 2004

53, M, n/a

Cytarabine, daunorubicin

+

AML

Membranous GN

[16], 2010

9, M, M3

Cytarabine, idarubicin, etoposide, ATRA

–

Anthracycline

FSGS

[1], 2012

3, M, M3

Cytarabine, daunorubicin, ATRA

–

n/a

Our case

5, M, M3

Cytarabine, daunorubicin, thioguanine,
ATRA, and dexamethasone

–

ATRA
syndrome
Anthracycline

Reference,
year

Age, sex,
FAB

[10], 1972

n/a

Steroids
+
ChemoTx
+
Steroids
+
Steroids
+
ChemoTx
+
Steroids
+

Outcome
Death at 6 days
(renal failure)
CR, relapse at
2 m and death
Early death
Death at 26
days (sepsis)
Death at 16
days (DAH)
Death at 14
months (sepsis)
Death at
6 months
(DAH)
n/a
CR at 2 years
CR
CR

6MP, 6-mercaptopurine; AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; ChemoTx, chemotherapy; CR, complete remission; DAH, diffuse
alveolar hemorrhage; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; GN, glomerulonephritis; M-CSF, macrophage
colony-stimulating factor; MCD, minimal change disease; n/a, not available; NS, nephrotic syndrome; Tx, treatment.
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and function due to cytokine release has been proposed as
a mechanism of nephrotic syndrome during ATRA-induced
differentiation syndrome in APL [1]. A causal relationship
between NS and AML is further supported by the response
of proteinuria to chemotherapy for AML and the association
between higher leukemia burden and more proteinuria
[1, 2]. Anthracyclines have been proposed as a culprit in the
development of NS following treatment of AML since they
can cause acute renal tubulointerstitial toxicity [3, 4]. Also,
adriamycin rapidly increases the expression of the ligands
on podocytes for advanced glycation end products, leading
to podocyte stress and glomerulosclerosis in mouse
models [5]. Adriamycin is now often used to induce experimental FSGS [6, 7]. Finally, NS in AML may reﬂect a local
immune complex-mediated process [8, 9]. Given the
absence of proteinuria before AML treatment in our patient,
we believe daunorubicin was the most likely cause of NS in
the present case. However, a direct effect of ATRA (e.g. terminal differentiation of promyelocytes and toxic effects of
the released granules) cannot be ruled out. He had no signs
of recurrent NS after re-exposure to chemotherapy, suggesting re-challenge may be safe in drug-induced NS.

